| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Pacific Biosciences (NASDAQ:PACB) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 3 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.4, a high estimate of $12.00, and a low estimate of $2.00. Experiencing a 50.56% decline, the current average is now lower than the previous average price target of $8.90.
A comprehensive examination of how financial experts perceive Pacific Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Westenberg | Piper Sandler | Lowers | Neutral | $2.00 | $6.50 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $2.00 | $3.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Neutral | $2.50 | $7.00 |
| Eve Burstein | Bernstein | Lowers | Outperform | $2.50 | $9.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Neutral | $2.50 | $7.00 |
| Sung Ji Nam | Scotiabank | Lowers | Sector Outperform | $8.00 | $15.00 |
| Daniel Brennan | TD Cowen | Lowers | Buy | $2.50 | $12.00 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $3.00 | $8.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $7.00 | $9.00 |
| John Sourbeer | UBS | Lowers | Buy | $12.00 | $12.50 |
Capture valuable insights into Pacific Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Pacific Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Pacific Biosciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 113.35%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Pacific Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -140.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacific Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -11.2%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.5%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.33, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PACB
